Premium
F2‐02‐03: NF‐L IN TRAUMATIC BRAIN INJURY/ CONCUSSION FOR PRECISION MEDICINE AND AS A PREDICTOR OF OUTCOME
Author(s) -
Blennow Kaj
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.2617
Subject(s) - concussion , chronic traumatic encephalopathy , traumatic brain injury , medicine , biomarker , athletes , diffuse axonal injury , physical therapy , physical medicine and rehabilitation , oncology , poison control , injury prevention , emergency medicine , psychiatry , biochemistry , chemistry
Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) clinical research consortium, a North American research consortium involving 18 clinical centers with an enrollment of over 900 participants as of December, 2017. I will compare these results with recent reports from similar studies in the UK and EU. Results:Plasma NfL levels measured on the Simoa platform will be reported. These studies are currently underway. Conclusions:NfL is a useful biomarker for FTLD syndromes. Further efforts to qualify this biomarker for use in clinical trials may be warranted.